AD new drug delayed listing development trapped Baijian or will be through mergers and acquisitions to broaden the pipeline?

Judging by McDonnell's record, there may be a hint that Mr. Perkin will make a strategic change in his business.
has completed only one acquisition in three years, and the board has been unhappy that Jeffery Capello has served as Chief Financial Officer and Executive Vice President of Perpetual since December 2017. In addition to going through a clinical termination to a reboot of the Alzheimer's drug Aduka monotoma,
completed a $877 million acquisition of gene therapy company Nightstar Therapeutics and 18 deals focused on early clinical practice, in addition to going through a clinical termination to a reboot, to the upcoming listing of a "peak circuit"-like listing.
industry speculation that the personnel change stake could suggest that The Company is changing its business development strategy, and the board is unhappy that only one major acquisition has been completed during Capello's tenure. "McDonnell has extensive expertise in creating value and strategic finance,"
said in his announcement of his appointment.
it is understood that in June 2019, Baijian completed a nearly 70 per cent premium acquisition of Nightstar in a $800 million deal that gave Peran to acquire two late-stage gene therapy products in the retina.
acquisition was actually part of a wave of gene therapy from the lab to the clinic.
2018, the acquisition of gene therapy companies has been a trend, with the $800million acquisition of Nightstar not prominent, billions of dollars in big deals, Sanofi's $11.6 billion acquisition of Bioverativ, Novartis's $8.7 billion acquisition of AveXis, Roche's $4.3 billion acquisition of Spark... Compared with these huge acquisitions, the volume of the acquisition of Baijian is obviously insufficient.
has completed a $1 billion acquisition in his last three years in office, and is not in the mix about the planning of Baijian's change of business development strategy.
, and Michael McDonnell, CHIEF financial officer of IQVIA, has a markedly different resume.
joined Quintiles in 2015, a year after Quintiles merged with IMS to form IQVIA, and IQVIA completed three acquisitions between 2017 and 2019.
McDonnell worked at PwC for 14 years before joining Quintiles as a certified public accountant.
02 the expiration of the patent, the new drug is not performing well, Baijian urgently need to broaden the pipeline, and The current situation of Baijian also shows that it urgently needs to make strategic adjustments and introduce relevant personnel.
22 in the second quarter of the earnings conference call, Baijian CEO Michel Vounatsos said that the vumerity so far performance is disappointed, the new crown outbreak disrupted the deployment of the drug, the next five months will be the key to the development of the drug.
Vumerity, which went public in the U.S. in November 2019, has made only $11 million in profitsince.
early on, Biogen executives touted the drug as a successor to tecfidera, which is more effective and accessible.
but the drug had sales of just $2 million in the first quarter and just $9 million in the second quarter.
(chart source: Euronews) Vounatsos believes that under the new crown outbreak, the decline in patient segregated patients' home isolation and doctor visits has made the drug's sales low, while the market for multiple sclerosis is highly competitive.
Despite Biogen's large share of the field, companies such as Novartis, Roche and Sanofi have continued to dominate the market over time.
both in terms of indications and market performance so far, Biogen's new drug, Vumerity, does not appear to be more competitive than novartis's new drug, Mayzent, which went on sale in the same year.
not just the pressure on the new drug Vumerity, but also when the high-profile New Alzheimer's drug, Aducanumab, will be put on the market.
a clinical trial of Aducanumab, which was discontinued in early 2019 due to poor clinical data, returned at the end of 2019, bringing a stock surge to Baijian, with some agencies predicting that the drug will become the first treatment, with annual sales reaching billions of dollars.
In April this year, in the first quarter of the year, it was announced that Aducanumab will be delayed until the third quarter of this year to submit a listing application to the FDA, the news announced that the day of the company's share price plummeted.
analysts also believe that a delay, Aducanumab approved for listing may be in 2022.
, the "patent expiration" and "market squeeze" that have caused headaches for many pharmaceutical companies are also problems that Baijian is facing.
's 2019 results, tecfidera, the heavy-duty multiple sclerosis drug, accounted for nearly 50 percent of the company's revenue.
2019 Mylan launched a patent challenge to The Company, and in June, a federal court in West Virginia ruled that Tecfidera's 514 patents were invalid due to a lack of written description, sending Peran's shares down more than 7 percent on the day.
not only the expiration of patents, but also the squeeze on the market is also a threat to the company.
2016, Baijian launched Spinraza, the first drug for spinal muscular dystrophy, which contributed $884 million in sales in its first year of market, with sales of $2,097 million in 2019, up 22 percent from a year earlier, while the drug grew by 98 percent in 2018.
reason stood out, in May 2019, Novartis launched Zolgensma, the world's first gene therapy for spinal muscular dystrophy, which, despite its high price, has generated $361 million in sales in just six months.
faced with the dilemma of not performing as well as expected, patents expiring, the market being squeezed... Mergers and acquisitions may be the pursuit of the future expansion pipeline of Baijian. "We will remain active in business development and mergers and acquisitions," vounatsos,
, said in a earnings call.
original title: Baijian CFO will be replaced! AD new drug delayed market, development is trapped, Baijian or will be through mergers and acquisitions to broaden the pipeline?